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Recommended vaccine formulation
The following strains have been recommended by the World 
Health Organization for the 2006 southern hemisphere influenza 
season: 
•  A/New Caledonia/20/99 (H1N1)-like virus
•  A/California/7/2004 (H3N2)-like virus 
•  B/Malaysia/2506/2004-like virus.
   The actual viral strains recommended for the vaccine for each 
component are as follows: 
•   NYMC X-157 recommended for the A/California/7/2004 
(H3N2)-like strain 
•   IVR-116 recommended for the A/New Caledonia/20/99 
(H1N1)-like strain
•   B/Malaysia/2506/2004 recommended for the B/ 
Malaysia/2506/2004-like strain.
   Vaccines should contain 15 μg of each haemagglutinin antigen 
in each 0.5 ml dose.
Indications
1.   Persons (adults or children) who are at high risk for 
influenza and its complications because of underlying 
medical conditions and who are receiving regular medical 
care for conditions such as chronic pulmonary and cardiac 
disease, chronic renal diseases, diabetes mellitus and 
similar metabolic disorders, and individuals who are 
immunosuppressed (including HIV-infected persons with 
CD4 counts above 200/ml).
2.   Residents of old-age homes, chronic care and rehabilitation 
institutions.
3.  Children on long-term aspirin therapy.
4.   Medical and nursing staff responsible for the care of high-
risk cases.
5.   Adults and children who are family contacts of high-risk 
cases.
6.  All persons over the age of 65 years. 
7.   Women who would be in the second or third trimester of  
pregnancy during the influenza season.  Pregnant women 
with medical conditions placing them at risk for influenza 
complications should be immunised at any stage of 
pregnancy.
8.   Any persons wishing to protect themselves from the risk of 
contracting influenza, especially in industrial settings, where 
large-scale absenteeism could cause significant economic 
losses.
Dosage
•   Adults: whole or split-product or subunit vaccine – 1 dose 
IM.
•   Children (< 12 years): split-product or subunit vaccine – 1 
dose IM.
•   Children < 9 years of age who have never been vaccinated 
should receive 2 doses 1 month apart.
•   Children < 3 years of age should receive half the adult dose 
on 2 occasions separated 1 month apart.
Contraindications
•   Persons with a history of severe hypersensitivity to eggs.
•   Persons with acute febrile illnesses should preferably be 
immunised after symptoms have disappeared.
•   The vaccine should be avoided in the first trimester of 
pregnancy unless there are specific medical indications (see 
above, indication No. 7).
Timing
Vaccines should be given sufficiently early to provide protection 
for the winter.  A protective antibody response takes about 2 
weeks to develop.
Chemoprophylaxis
In cases where vaccine has not been administered, consideration 
should be given to the use of supplementary chemoprophylaxis 
with amantadine in certain high-risk individuals, e.g. patients 
with chronic lung and heart diseases.  Amantadine should be 
administered in a dosage of 200 mg daily in 2 divided doses for 
the duration of the epidemic activity, i.e. approximately 6 - 12 
weeks.  The dosage should be reduced in persons with renal 
disease and in those over the age of 65 years.
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